Interactions among drugs for HIV and opportunistic infections.
Piscitelli
S C
SC
Department of Pharmacy, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Gallicano
K D
KD
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000042:Absorption; D000890:Anti-Infective Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D004347:Drug Interactions; D016903:Drug Monitoring; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
D000890:Anti-Infective Agents; D017320:HIV Protease Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018894:Reverse Transcriptase Inhibitors; D003577:Cytochrome P-450 Enzyme System